SmartOmica, Tērbatas iela 36 - 4, Latvia Rīga LV-1011, Latvia.
Institute of Personalised and Translational Medicine, Ariel University, Israel Kiryat Hamada, Ariel, Israel.
Crit Rev Oncol Hematol. 2023 Jun;186:103997. doi: 10.1016/j.critrevonc.2023.103997. Epub 2023 Apr 14.
The Human Epidermal Growth Factor Receptor (HER) proteins family, which includes HER2, are membrane-bound receptors that activate many intracellular pathways associated with growth and development. When there are mutations in HER2, or when it becomes overexpressed, it can cause oncogenesis and offer differential prognosis and treatment across almost all cancer types. Both mutations in HER2 and its overexpression have distinct mechanisms by which they can cause these effects in cancers. This review outlines how HER2's normal pathway is altered in both overexpression and mutation and compiles all the well-known mechanisms by which HER2 can cause oncogenesis. Finally, this review briefly outlines how HER2 mutants and HER2 overexpression is detected, and how their detection can lead to different prognosis and treatment in cancers.
人类表皮生长因子受体（HER）蛋白家族，包括 HER2，是膜结合受体，可激活与生长和发育相关的许多细胞内途径。当 HER2 发生突变或过度表达时，它可能导致肿瘤发生，并在几乎所有癌症类型中提供不同的预后和治疗。HER2 的突变和过度表达都有其独特的机制，导致癌症中出现这些效应。这篇综述概述了 HER2 的正常途径在过度表达和突变中是如何改变的，并总结了 HER2 导致肿瘤发生的所有已知机制。最后，这篇综述简要概述了如何检测 HER2 突变体和 HER2 过表达，以及它们的检测如何导致癌症中不同的预后和治疗。
